Skip to main content
. 2017 Dec 18;3(2):e000491. doi: 10.1136/rmdopen-2017-000491

Figure 1.

Figure 1

Patient disposition. *Patients who switched multiple times were not included in this analysis; **for patients switching treatment regimens, discontinuations from study within 30 days of treatment switch are reported; ***‘other reasons’ included patients lost to follow-up, patients no longer willing to participate, withdrawals due to pregnancy, protocol violations and study termination by sponsor. AE, adverse event; BID, twice daily; csDMARD, conventional synthetic disease-modifying antirheumatic drug; LTE, long-term extension.